BioScrip, Inc. (NASDAQ: BIOS) announced today that it has been awarded specialty pharmacy and mail service pharmacy accreditation from URAC, a Washington, D.C.-based health care accrediting organization that establishes quality standards for the health care industry.
“Going through the process challenged us to find better ways to serve our customers, and it is a constant reminder that our first responsibility is to the patient and the quality of clinical service we provide.”
Specialty pharmacy and mail service pharmacy offers comprehensive oversight of the distribution, clinical management, and reimbursement of oral, injectable, and IV drug products for chronic conditions. Specialty pharmaceuticals represent the fastest growing segment of drug spending due to new product approvals, high unit costs, and increasing use.
"BioScrip is very pleased to have been awarded full accreditation for both specialty pharmacy and mail service pharmacy from URAC," stated Richard M. Smith, President and Chief Executive Officer of BioScrip. "Going through the process challenged us to find better ways to serve our customers, and it is a constant reminder that our first responsibility is to the patient and the quality of clinical service we provide."
URAC accreditation is granted to only a select group of organizations that demonstrate a commitment to quality standards. To achieve the accreditation for specialty pharmacy and mail service pharmacy, BioScrip participated in a complex application process which required a comprehensive review of BioScrip customer service and clinical pharmacy processes against a combined 146 quality standards by expert analysts.
"By applying for and receiving URAC accreditation, BioScrip has demonstrated a commitment to quality health care," said Alan P. Spielman, URAC president and CEO. "Quality health care is crucial to our nation's welfare and it is important to have organizations that are willing to measure themselves against national standards and undergo rigorous evaluation by an independent accrediting body."
Can community pharmacists reduce the incidence of skin cancer?